Not Medicare Enrolled

Dr. Jonathan Lockhart, M.D.

Psychiatry · Longview, TX
Speaking/Promotional
807 BAYLOR DR, Longview, TX 75601
9032958990
In practice since 2006 (19 years)
NPI: 1679678403 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lockhart from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lockhart? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Lockhart

Dr. Jonathan Lockhart is a psychiatry in Longview, TX, with 19 years in practice.

Between the years covered by Open Payments, Dr. Lockhart received a total of $763,744 from 38 pharmaceutical and/or device companies across 1820 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in psychiatry. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Lockhart is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice$ $763,744 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$763,744
Total received (2018-2024)
Avg $109,106/year across 7 years
Top 0% in TX for psychiatry
38
Companies
1,820
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$753,007 (98.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,863 (1.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,873 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$109,844
2023
$136,713
2022
$117,715
2021
$85,999
2020
$96,821
2019
$110,743
2018
$105,908

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$352,947
Allergan Inc.
$200,417
Allergan, Inc.
$93,078
AbbVie Inc.
$59,011
Eisai Inc.
$25,417
Otsuka America Pharmaceutical, Inc.
$17,720
Otsuka Pharmaceutical Development & Commercialization, Inc.
$5,084
Teva Pharmaceuticals USA, Inc.
$2,133
EISAI INC.
$1,873
Sunovion Pharmaceuticals Inc.
$1,228
Alkermes, Inc.
$654
Lundbeck LLC
$573
Vanda Pharmaceuticals Inc.
$491
ITI, Inc.
$473
Axsome Therapeutics, Inc.
$361
Takeda Pharmaceuticals U.S.A., Inc.
$341
Janssen Pharmaceuticals, Inc
$330
Neurocrine Biosciences, Inc.
$295
HARMONY BIOSCIENCES LLC
$151
E.R. Squibb & Sons, L.L.C.
$142
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$127
Merck Sharp & Dohme Corporation
$114
Corium, LLC
$97
Noven Therapeutics, LLC
$92
Supernus Pharmaceuticals, Inc.
$77
IDORSIA PHARMACEUTICALS US INC
$70
Bausch Health US, LLC
$70
Harmony Biosciences LLC
$67
Avanir Pharmaceuticals, Inc.
$66
Shire North American Group Inc
$64
Tris Pharma Inc
$34
Ironshore Pharmaceuticals Inc.
$30
Indivior Inc.
$29
Noven Pharmaceuticals, Inc.
$23
Genentech USA, Inc.
$21
LivaNova USA, Inc.
$20
Merck Sharp & Dohme LLC
$13
JAZZ PHARMACEUTICALS INC.
$12
Top 3 companies account for 84.6% of total payments
Associated products mentioned in payments ›
ABILIFY MAINTENA · APLENZIN · ARISTADA · AUSTEDO · Austedo XR · Auvelity · Azstarys · BELSOMRA · BRINTELLIX · CAPLYTA · COBENFY · Columvi · Dayvigo · Dyanavel XR · Entyvio · FANAPT · HETLIOZ · INGREZZA · INVEGA SUSTENNA · JORNAY PM · Jornay PM 20mg capsules (Bottle of 100) · LATUDA · LINZESS · LYBALVI · MYDAYIS · NUEDEXTA · Nuedexta · PERSERIS · QELBREE · QUVIVIQ · Qelbree · REXULTI · SPRAVATO · SUNOSI · Secuado · Sunosi · TRINTELLIX · Trintellix · UZEDY · VIIBRYD · VIVITROL · VNS Therapy · VRAYLAR · VYVANSE · WAKIX · Xelstrym
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (99%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in psychiatry and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for psychiatry in TX.

Looking for a psychiatry in Longview?
Compare psychiatrys in the Longview area by procedure volume, costs, and industry payment transparency.
Browse psychiatrys nearby

Geographic Context

Psychiatrys within 10 mi
7
Per 100K population
5.6
County median income
$64,809
Nearest hospital
CHRISTUS GOOD SHEPHERD MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Lockhart is a psychiatry, and high industry engagement (speaking/promotional, top 0%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Lockhart receive payments from pharmaceutical companies?
Yes. Dr. Lockhart received a total of $763,744 from 38 companies across 1,820 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Lockhart) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →